Avigen's Board of Directors to Review BVF Offer and Provide Recommendation
January 26, 2009 14:30 ET
|
Avigen, Inc.
ALAMEDA, Calif., Jan. 26, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, today confirmed that BVF Acquisition LLC, a wholly owned subsidiary of Biotechnology Value...
Avigen Retains Independent Strategic Advisors
January 14, 2009 13:32 ET
|
Avigen, Inc.
ALAMEDA, Calif., Jan. 14, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, announced today that its Board of Directors has retained two independent financial advisors...
Avigen Board and Management Comment On the Company's Strategic Plans
December 22, 2008 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Dec. 22, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, today announced that its Board of Directors and Management issued the following comments in...
Avigen Sells Early Stage Research Program in Hemophilia to Baxter
December 18, 2008 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Dec. 18, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, announced today that the company has sold the rights to its early stage blood coagulation...
Avigen to Present At RBC Capital Markets Healthcare Conference
December 03, 2008 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Dec. 3, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, announced today that President and Chief...
Avigen Announces Restructuring and Strategic Direction
November 03, 2008 13:30 ET
|
Avigen, Inc.
ALAMEDA, Calif., Nov. 3, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced a significant restructuring of...
Avigen Reports Third Quarter 2008 Financial Results
October 28, 2008 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today reported financial results for its third...
Avigen Announces AV650 Did Not Meet Efficacy Endpoints in Phase 2b Clinical Trial for Spasticity in Patients With Multiple Sclerosis
October 21, 2008 06:30 ET
|
Avigen, Inc.
ALAMEDA, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced that the top-line data from...
Avigen Initiates Opioid Withdrawal Trial in Partnership With NIDA, Columbia University and the New York State Psychiatric Institute
October 15, 2008 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Oct. 15, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced the launch of an exploratory...
Avigen Completes Multi-Center AV650 Phase 2b Spasticity Trial in Patients With Multiple Sclerosis
September 18, 2008 08:00 ET
|
Avigen, Inc.
ALAMEDA, Calif., Sept. 18, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced the completion of the...